Table 2.
Baseline characteristics of virus-positive and virus-negative patients.
| Virus-positive |
Virus-negative |
p value | |
|---|---|---|---|
| (n = 26) | (n = 17) | ||
| Month of exacerbation | 0.775 | ||
| – November 2009 – December 2009 – January 2010 – February 2010 |
9 (34.6) | 7 (41.2) | |
| 6 (23.1) | 2 (11.8) | ||
| 8 (30.8) | 5 (29.4) | ||
| 3 (11.5) | 3 (17.6) | ||
| Symptom duration at date of swab | |||
| – Mean (range) – Median (IQRa) |
7.5 (2–21) | 12.3 (2–21) | 0.066 |
| 6 (3–10) | 14 (2.5–21) | 0.290 | |
| Patient characteristics at enrollment | |||
| Age, y, median (IQR) | 6.9 (3.8–13.5) | 13 (6.5–15.4) | 0.047 |
| Male | 14 (53.8) | 4 (23.5) | 0.029 |
| Weight-for-recumbent length percentile | |||
| – Median (IQR) | 50 (30–82.5) | – | – |
| BMI percentile | |||
| – Median (IQR) | 24 (5–50) | 25 (10–50) | 0.474 |
| Homozygous DF508 | 6 (23.1) | 9 (52.9) | 0.588 |
| Baseline predicted FEV1 | 17 (65.4) | 15 (88.2) | 0.268 |
| – Median (IQR) | 68 (57.5–87) | 85 (63–94) | 0.243 |
| Upper respiratory tract infection | 11 (42.3) | 7 (41.2) | 0.941 |
| Fever | 12 (46.2) | 2 (11.8) | 0.019 |
| Comorbidities | |||
| Pancreatic insufficiency | 17 (65.4) | 13 (76.5) | 1.0 |
| CF-related diabetes | 2 (7.7) | 1 (5.9) | 1.0 |
| ABPAb | 4 (15.4) | 5 (29.4) | 0.462 |
| Bacterial colonization at enrollment | |||
| Throat swabs (n = 16) | 12 | 4 | |
| – Staphylococcus aureus | 4 (33.3) | 1 (25) | 0.755 |
| – Pseudomonas aeruginosa | – | – | – |
| Sputum samples (n = 27) | 14 | 13 | |
| – Staphyloccocus aureus | 8 (57.1) | 9 (69.2) | 0.340 |
| – Pseudomonas aeruginosa | 2 (14.3) | 2 (15.4) | 1 |
| Influenza vaccination status | |||
| Received seasonal influenza vaccine | 6 (23.1) | 6 (35.3) | 0.667 |
| Received pH1N1 vaccine | 9 (34.6) | 11 (64.7) | 0.291 |
Note. Data are n (%) unless otherwise indicated.
a
Interquartile range (25th–75th percentile).
b
Allergic bronchopulmonary aspergillosis.